Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Core Insights - Erasca, Inc. has announced a clinical trial collaboration with Tango Therapeutics to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Tango's PRMT5 inhibitor, vopimetostat [1][2] Group 1: Clinical Trial Collaboration - The collaboration involves a Phase 1/2 clinical trial targeting patients with MTAP-deleted pancreatic cancer or MTAP-deleted RAS-mutant non-small cell lung cancer (NSCLC) [2][3] - Erasca will supply ERAS-0015 at no cost, while Tango will act as the trial sponsor [1][2] Group 2: Product Details - ERAS-0015 is designed to inhibit RAS signaling and has shown early clinical activity at a dose of 8 mg once daily, with confirmed and unconfirmed responses across multiple tumor types [4] - Preclinical studies indicate that ERAS-0015 has 8-21 times higher binding affinity to cyclophilin A compared to RMC-6236 and demonstrates approximately 5 times greater potency in RAS inhibition [4] Group 3: Market Opportunity - Nearly all MTAP-deleted pancreatic cancers and 30% of MTAP-deleted NSCLC tumors have co-occurring RAS mutations, indicating a significant market need for effective treatments targeting these cancers [3] - The combination of ERAS-0015 and vopimetostat may provide a dual-targeted approach to enhance treatment efficacy and reduce resistance in difficult-to-treat cancers [3]